

The Oncolytic Virus Landscape 2017: an Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities

<https://marketpublishers.com/r/OE0B6FDEA1FEN.html>

Date: January 2017

Pages: 225

Price: US\$ 2,400.00 (Single User License)

ID: OE0B6FDEA1FEN

Abstracts

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US\$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also „freed“ tumor specific neoantigens, indirectly acting as a cancer vaccine.

However, the efficacy of oncolytic viruses still was modest, but can be improved when combined with immune checkpoint inhibitors. This led to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. As a consequence, total venture equity and private investments into oncolytic virus companies in 2016 was nearly 17-fold higher than in the year 2010.

Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo. Based on experience with several virus families over the last decades, a few virus families crystallized as well suitable backbones to carry more and more transgenes to express proteins or even single chain antibodies. This would position oncolytic viruses as

independent therapeutics and could compete with immuno-oncology compounds and cancer vaccines.

This report „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects, business deals and private and public financing rounds. The report analyzes the Oncolytic Virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing and (initial) public offerings.

This report has been built in a bottom-up way by desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

Selection of oncolytic virus strains

Design & construction of engineered oncolytic viruses

Herpes simplex virus (HSV) family

Adenovirus-based oncolytic viruses

Oncolytic Vaccinia Viruses, Vesicular Stomatitis Viruses, Newcastle Disease Viruses & Others

Profiles of 45 oncolytic viruses in development and on the market;

Analysis of the pipeline of oncolytic viruses

Comparison of clinical development paths

Combination trials of oncolytic viruses with immune checkpoint inhibitors

Combination with other anticancer therapeutics

Armed oncolytic viruses

Tumor indication of oncolytic viruses under study

Way of administration of oncolytic viruses in clinical studies

Profiles of 45 companies active in the field of oncolytic viruses

Pharma & Biotech vs four generations of oncolytic virus companies

Stakeholder analysis within each peer group

Sources of oncolytic virus technologies

Sources of non-dilutive financing including partnering deals

Analysis of venture and private equity financing rounds

Listing on stock exchange for access to capital

Mergers and acquisition in the field

Trends in the further research and development of oncolytic viruses

Who will benefit from the report?

Venture capital, private equity and investment managers;

Financial analysts;

CFO;

Business development and licensing (BDL) specialists;

Marketing managers;

CEO, COO and managing directors;

Corporate strategy, product and portfolio analysts and managers;

Chief Technology Officer;

Cell technology and manufacturing specialists;

Clinical and preclinical development specialists.

Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION & OVERVIEW

3 SELECTION, DESIGN & CONSTRUCTION OF ONCOLYTIC VIRUSES

3.1 Herpes Simplex Virus (HSV) – based Oncolytic Viruses

3.2 Adenoviruses – based Oncolytic Viruses

3.3 Vaccinia Virus - Based Oncolytic Viruses

3.4 Vesicular Stomatitis Virus - based Oncolytic Viruses

3.5 Newcastle Disease Virus - based Oncolytic Viruses

3.6 Various Oncolytic Viruses

4 PROFILES OF ONCOLYTIC VIRUSES

4.1 HSV-based Oncolytic Viruses

4.1.1 Imlygic; talimogene laherparepvec; T-Vec; OncoVEX(GM-CSF)

4.1.2 G47?

4.1.3 HF10; TB-1401

4.1.4 HSV1716; seprehvir

4.1.5 HSV-Rb-p450

4.1.6 BV-2711

4.1.7 ONCR-001

4.2 Adenovirus-based Oncolytic Viruses

4.2.1 Oncorine

4.2.2 CG0070

4.2.3 DNX-2401

4.2.4 OBP-301; telomelysin

4.2.5 ONCOS-102

4.2.6 Enadenotucirev; ColoAd1

4.2.7 Adenoviral VirRx 007; INGN 007; VRX-007

4.2.8 VCN-01

4.2.9 LOAd703

4.2.10 H103

4.2.11 NG-348

4.2.12 ORCA-010

4.2.13 TILT-123

- 4.2.14 UIO-112
- 4.2.15 TILT-324
- 4.2.16 DNX-2440; Delta-24-RGDOX
- 4.2.17 DNX-2450
- 4.2.18 OBP-702
- 4.3 Vaccinia Virus-based Oncolytic Viruses
 - 4.3.1 Pexastimogene devacirepvec; Pexa-Vec; JX-594; TG6006
 - 4.3.2 GL-ONC1
 - 4.3.3 JX-929; vvDD
 - 4.3.4 TG6002
 - 4.3.5 WO-12
- 4.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
 - 4.4.1 MG1 Maraba/MAGE-A3 (MG1MA3)
 - 4.4.2 VSV-IFNbeta
 - 4.4.3 VSV-IFNbeta-NIS
 - 4.4.4 VSV-GP
- 4.5 Newcastle Disease Virus-based Oncolytic Viruses
 - 4.5.1 NDV-HUJ
 - 4.5.2 PV701
 - 4.5.3 recNDVGM-CSF
- 4.6 Various Oncolytic Viruses
 - 4.6.1 Rigvir
 - 4.6.2 Reolysin; pelareorep
 - 4.6.3 CAVATAK; CVA21
 - 4.6.4 MV-NIS
 - 4.6.5 NTX-010; SVV-001
 - 4.6.6 H-1PV
 - 4.6.7 PVS-RIPO
 - 4.6.8 MYX-135
- 4.7 Stem Cell-delivered Oncolytic Viruses
 - 4.7.1 TBX.OncV (CRad-Survivan-pk7)
 - 4.7.2 MSC-ICOVIR-5

5 ANALYSIS OF ONCOLYTIC VIRUS PIPELINE

- 5.1 Overview of the Pipeline of Oncolytic Viruses
- 5.2 Approved and Marketed Oncolytic Viruses
- 5.3 Late Stage Development of Oncolytic Viruses
- 5.4 Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-

Tumor Agents

5.5 Armed Oncolytic Viruses

6 COMPANY PROFILES

6.1 Pharma & Biotech

6.1.1 Amgen

6.1.2 Astellas Pharma

6.1.3 AstraZeneca

6.1.4 Boehringer Ingelheim

6.1.5 Bristol-Myers Squibb

6.1.6 Celgene

6.1.7 Daiichi Sankyo

6.1.8 Green Cross

6.1.9 Jiangsu Hengrui

6.1.10 Lee Pharma

6.1.11 Medigen Biotechnology

6.1.12 Merck

6.1.13 Otsuka Pharmaceutical Co

6.1.14 Pfizer

6.1.15 Roche

6.2 First Generation Oncolytic Virus Companies

6.2.1 Cold Genesys

6.2.2 Genelux

6.2.3 Latima

6.2.4 Multivir/VirRx

6.2.5 Neotropix

6.2.6 Oncolytics Biotech

6.2.7 Shanghai Sunway Biotech

6.2.8 SillaJen

6.2.9 Takara Bio

6.2.10 Theravir

6.2.11 Virttu Biologics & TNK Therapeutics

6.2.12 Wellstat Biologics

6.3 Second Generation Oncolytic Virus Companies

6.3.1 DNATRIX

6.3.2 Oncolys BioPharma

6.3.3 ORCA Therapeutics

6.3.4 Oryx

- 6.3.5 Targovax
- 6.3.6 VCN Biosciences
- 6.3.7 Viralytics
- 6.4 Third Generation Oncolytic Virus Companies
 - 6.4.1 Benevir BioPharm
 - 6.4.2 Lokon Pharma
 - 6.4.3 PsiOxus Therapeutics
 - 6.4.4 Transgene
- 6.5 Fourth Generation Oncolytic Virus Companies
 - 6.5.1 Duke University Start-Up Company
 - 6.5.2 IGNITE Immunotherapy
 - 6.5.3 Oncorus
 - 6.5.4 Replimmune
 - 6.5.5 TILT Biotherapeutics
 - 6.5.6 Turnstone Biologics
 - 6.5.7 Unleash Immuno Oncolytics
 - 6.5.8 ViraTherapeutics
 - 6.5.9 Vyriad
 - 6.5.10 Western Oncolytics

7 STAKEHOLDER ANALYSIS

- 7.1 Pharma & Biotech
- 7.2 First Generation Oncolytic Virus Companies
- 7.3 Second Generation Oncolytic Virus Companies
- 7.4 Third Generation Oncolytic Virus Companies
- 7.5 Fourth Generation Oncolytic Virus Companies

8 FINANCING & PARTNERING

- 8.1 Grants, Credits & Donations
- 8.2 Venture Capital, Private Equity & Private Placements
- 8.3 Partnering Deals
- 8.4 Listing on the Stock Market
- 8.5 Mergers & Acquisitions

9 TRENDS & OPPORTUNITIES

10 REFERENCES

Tables

TABLES IN THE TEXT:

- Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses
- Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses
- Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses
- Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses
- Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses
- Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses
- Table 7: Current Company-Sponsored Clinical Trials of T-Vec
- Table 8: Clinical Trials of ColoAd1
- Table 9: Clinical Trials with JX-594
- Table 10: Clinical Trials with GL-ONC1
- Table 11: Clinical Trials of CAVATAK (CVA21)
- Table 12: Clinical Trials with MV-NIS
- Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family
- Table 14: Profile of Approved and Marketed Oncolytic Viruses
- Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results
- Table 16: Approved Indications of Immune Checkpoint Inhibitors
- Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
- Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
- Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics
- Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase
- Tables 21a and 21b: Indications and Frequency and Way of Administration of Oncolytic Viruses in Active and/or Positive Completed Clinical Studies
- Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses
- Table 23: Immuno-Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses
- Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses
- Table 25: First Generation Oncology Virus Companies and their Sources of Technology
- Table 26: Second Generation Oncology Virus Companies and their Sources of

Technology

Table 27: Third Generation Oncology Virus Companies and their Sources of Technology

Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology

Table 29: Grants, Credits & Donations

Table 30: Financing by Venture Capital, Private Equity and Other Private Placements

Table 31: Collaboration & Licensing Agreements

Table 32: Companies Listed on Stock Exchange & Offerings

Table 33: Mergers & Acquisitions

COMPANIES MENTIONED IN THE REPORT

Amgen

Astellas Pharma

AstraZeneca (MedImmune)

Bayer

Benevir Biopharm

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Cold Genesys

Daiichi Sankyo

DNatrix

Duke University start-up Company

GeneLux

Green Cross

Grifols

GSK (GlaxoSmithKline)

IGNITE Immunotherapy

Jiangsu Hengrui

Latima

Lee's Pharma

Lokon Pharma

Medigen Biotechnology

Merck

Multivir

Neotropix

Oncolys BioPharma

Oncolytics Biotech
Oncorus
Orca Therapeutics
Oryx
Otsuka Pharmaceutical Co
Pfizer
Profectus Biosciences
PsiOxus
Replimune
Roche
Shanghai Sunway Biotech
SillaJen
Sotio
StemImmune
StingInn
Takara Bio
Targovax
TheraBiologics
Theravir
TILT Biotherapeutics
Transgene
Turnstone Biologics
Unleash Immuno Oncolytics
VCN Biosciences
Viralytics
ViraTherapeutics
Virtu Biologics (TNK Therapeutics)
Vyriad
Wellstat Biologics
Western Oncolytics

I would like to order

Product name: The Oncolytic Virus Landscape 2017: an Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities

Product link: <https://marketpublishers.com/r/OE0B6FDEA1FEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OE0B6FDEA1FEN.html>